Evidence map›Paper›PMID 38326863›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis.

Ke Chen, Jingcheng Zhang, Lei Meng, Lingshang Kong, Ming Lu, Zhengguang Wang, Wenbin Wang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. mFrontiers in cell and developmental biology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Ke Chen *Vascular Surgery Department, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China.
Jingcheng Zhang *Department of Surgery, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.
Lei Meng *General Surgery Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Lingshang Kong *General Surgery Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Ming LuGeneral Surgery Department, Anhui Provincial Hospital, Hefei, China.
Zhengguang WangGeneral Surgery Department, The First Affiliated Hospital of Anhui Medical University, Hefei, China. wangzhengguang@ahmu.edu.cn.
Wenbin WangGeneral Surgery Department, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. nihao22009256@163.com.
Anhui Medical University · CNAnhui Provincial Hospital · CNKlinikum rechts der Isar · DENanjing Drum Tower Hospital · CN

Funding

Clinical Medicine Discipline construction project of Anhui Medical University 9301001807Key project of Anhui Translational Medicine Research Institute 2022zhyx-B08Natural Science Foundation in Anhui Province of China 2008085MH279
6 · The paper itself

Abstract

backgroundm6A modification is currently recognized as a major driver of RNA function that maintains cancer cell homeostasis. Long non-coding (Lnc) RNAs control cell proliferation and play an important role in the occurrence and progression of colorectal cancer (CRC). ZCCHC4 is a newly discovered m6A methyltransferase whose role and mechanism in tumors have not yet been elucidated.

methodsThe EpiQuik m6A RNA methylation kit was used to detect the level of total RNA m6A in six types of digestive tract tumors. The Kaplan-Meier method and receiver operating characteristic curve were used to evaluate the prognostic and diagnostic value of the newly discovered m6A methyltransferase, ZCCHC4, in CRC. The effects on CRC growth in vitro and in vivo were studied using gain- and loss-of-function experiments. The epigenetic mechanisms underlying ZCCHC4 upregulation in CRC were studied using RIP, MeRIP-seq, RNA pull-down, and animal experiments.

resultsWe reported that the ZCCHC4-LncRNAGHRLOS-KDM5D axis regulates the growth of CRC in vitro and in vivo. We found that ZCCHC4 was upregulated in primary CRC samples and could predict adverse clinical outcomes in patients with CRC. Mechanistically, ZCCHC4 downregulated LncRNAGHRLOS to promote CRC tumorigenesis. As a downstream molecule of LncRNAGHRLOS, KDM5D directly controls CRC cell proliferation, migration, and invasion.

conclusionThis study suggests that the ZCCHC4 axis contributes to the tumorigenesis and progression of CRC and that ZCCHC4 may be a potential biomarker for this malignancy.

Indexed as

AdenineColorectal NeoplasmsRNA, Long NoncodingAnimalsCarcinogenesisCell Line, TumorCell Transformation, NeoplasticDown-RegulationEpigenesis, GeneticHistone DemethylasesHumansMethyltransferasesMinor Histocompatibility AntigensRNAtRNA Methyltransferases6-methyladenineAdenineHistone DemethylasesKDM5D protein, humanMethyltransferasesMinor Histocompatibility AntigensRNARNA, Long NoncodingtRNA MethyltransferasesZCCHC4 protein, humanColorectal cancerKDM5DLncRNAGHRLOSN6-methyladenosineZCCHC4

Identifiers

PMID38326863
PMCPMC10848513
OpenAlexW4391611138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.